Subrat Kumar Acharya

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 546 citations

Pharmacy, Infectious Diseases, Pharmacology +12

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry Lik‐Yuen Chan, Scott Fung, Wai Kay Seto et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 458 citations

Pharmacy, Infectious Diseases, Pharmacology +11

Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death

Subrat Kumar Acharya, Praveen Sharma, Rajbir Singh et al. · Journal of Hepatology · 2006 · 307 citations

Medicine, Infectious Diseases, Internal Medicine +13

Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens†‡

Masaya Sugiyama, Yasuhito Tanaka, Takanobu Kato et al. · Hepatology · 2006 · 289 citations · Full text

Life Sciences, Microbiology, Molecular Biology +14